Market Intelligence for KATP Channel Modulators in Diabetes, Congenital Hyperinsulinism, and Neurological Indications.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SUR1/ABCC8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | SUR1/ABCC8 Full-Length Lentivirus Premade Particles (High titer >10^8 TU/mL) and Promise-ORF Lentivirus for stable cell line generation. HEK293T packaging. | View SUR1 Products |
| Antigen (SUR1 ECD) | SUR1/ABCC8 ECD / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View SUR1 Products |
| Antigen (Selectivity Panel) | SUR2A/SUR2B (ABCC9) ECD-Fc Fusion. For off-target screening against cardiac/vascular isoforms. High Purity (>95%). | View ABCC9 Products |
| Benchmark Antibody | Anti-SUR1/ABCC8 recombinant positive control for flow cytometry and IHC validation. | View SUR1 Products |
| Co-Expression Partner | Kir6.2 (KCNJ11) Lentivirus / ORF Plasmid. Obligatory partner for functional KATP channel assembly. | View KCNJ11 Products |
| Mutant Library | SUR1 CHI-Mutant Lentivirus Panel (E1506K, R1379C, A116P). Congenital Hyperinsulinism variants for precision rescue assays. | View SUR1 Products |
| Validator | SUR1/ABCC8 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View SUR1 Products |
| Related Target (KATP) | Kir6.1 (KCNJ8). Vascular smooth muscle KATP partner; alternative channel composition. | View KCNJ8 Products |
| Related Target (Metabolic) | GLP1R. Synergistic metabolic pathway for glycemic control. | View GLP1R Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-TMD Complex Folding (17 TMDs) | Full-Length Lentivirus for native membrane insertion; HEK293 expression preserves glycosylation required for trafficking. |
| Functional Channel Assembly (SUR1 + Kir6.2) | Dual-promoter Lentivirus or matched pair available; validated for Rubidium Flux and Patch Clamp applications. |
| Isoform Selectivity (SUR1 vs SUR2A/B) | ABCC9 (SUR2) ortholog proteins available for counter-screening; Endotoxin Controlled (<1 EU/μg). |
| Congenital Mutant Rescue Screening | CHI-specific mutant panel (Loss-of-function variants); Sequence Verified by NGS. |
| Lack of Controls | Clinical Benchmark Antibodies included for flow cytometry and IHC validation. |
| False Positives / Non-Specific Activity | Validated siRNA included for specificity and functional knockdown checks. |
Live SUR1/ABCC8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The SUR1/ABCC8 therapeutic landscape is transitioning from traditional sulfonylurea-based Type 2 Diabetes management toward precision channelopathy therapeutics. While glibenclamide (glyburide) and glipizide remain standard-of-care KATP inhibitors, the field is pivoting toward two distinct frontiers: (1) genetic subtyping of Congenital Hyperinsulinism (CHI) for mutation-specific rescue therapies, and (2) CNS-targeted SUR1 inhibition for neurological ischemia and traumatic brain injury, where glibenclamide repurposing (e.g., BIIB093 for brain edema) has shown Phase II efficacy. As first-generation small molecules face generic competition, next-wave R&D emphasizes allosteric modulators with improved SUR1/SUR2 selectivity profiles to mitigate cardiovascular off-target effects, and gene correction strategies for ABCC8 loss-of-function mutations. Emerging players like Biogen and academic consortia are pushing into indication-specific modulators, while TRPM4 co-targeting gains traction in CNS applications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Sanofi, AstraZeneca, Remedy Pharmaceuticals, Biogen (BIIB093) | Type 2 Diabetes, CNS Ischemia, Brain Edema | Full-Length Channel Cell Lines (Lentivirus-based) for Patch Clamp and Rubidium Flux; SUR1/SUR2 Selectivity Panel |
| Channel Opener (Activator) | Diazoxide (generics), Mitokor | Congenital Hyperinsulinism, Hypoglycemia | Mutant Rescue Assays (CHI-variant Lentivirus); EC50 Shift Analysis |
| Gene Therapy (AAV) | University of Chicago, Biocrates, Academic/Emerging Biotech | Severe CHI (Neonatal), Neonatal Diabetes | Wild-type vs Mutant Protein Expression Validation; Anti-SUR1 Antibodies |
| Antisense/siRNA | Academic Consortia | Hyperinsulinism subtypes | Validated siRNA Controls (TarMart Validator Set) |
| Biologics/mAbs | Early Discovery | Targeted Delivery | Internalization/Binding (Need ECD fragments and Flow Cytometry controls) |
Key Functional Domains and Key Mutations
SUR1 (ABCC8) is a multi-pass membrane protein belonging to the ABC transporter superfamily. Its functional domains include three ABC transmembrane regions (ABC transmembrane type-1 1, ABC transmembrane type-1 2, and ABC transporter 1) as annotated in UniProt Q09428. Clinically relevant mutations are concentrated in the HHF1 (hyperinsulinemic hypoglycemia familial 1) region. Key missense variants include rs781059815 and rs200670692, in addition to the frequently studied congenital hyperinsulinism (CHI) mutants E1506K, R1379C, and A116P. These mutations impair channel trafficking or gating, making them critical targets for precision rescue therapeutics.
Cross-Sell and Related Targets
Based on KATP channel assembly and pathway crosstalk, the following related targets are recommended for cross-selling:
- KCNJ11 (Kir6.2): Obligatory pore-forming partner for SUR1; >90% of SUR1 customers require Kir6.2 co-expression for functional assays.
- ABCC9 (SUR2A/SUR2B): Cardiac and vascular isoforms required for selectivity counter-screening per FDA guidance.
- KCNJ8 (Kir6.1): Forms vascular smooth muscle KATP with SUR2; needed for cardiovascular safety packages.
- GLP1R: Indirect competitor in diabetes; useful for benchmarking and combination studies.
- TRPM4: SUR1 co-assembles with TRPM4 in CNS injury; emerging off-target screening target.